Related Experiment Videos
Drug-associated disease: hematologic dysfunction.
Erik R Vandendries1, Reed E Drews
1Division of Hemostasis/Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. Erik.Vandendries@parexel.com
Critical Care Clinics
|May 9, 2006
Summary
Identifying drug-induced hematologic dysfunction in critical illnesses is challenging. Clinicians must consider all medications, as drugs can cause severe blood disorders like aplastic anemia and thrombocytopenia.
Area of Science:
- Hematology
- Critical Care Medicine
- Pharmacology
Background:
- Hematologic dysfunction is common in critical illnesses, encompassing conditions like thrombocytopenia, anemia, neutropenia, thromboses, and coagulopathy.
- Distinguishing drug-induced hematologic issues from other causes presents a significant clinical challenge.
Purpose of the Study:
- To highlight the importance of considering drug-induced causes in patients with acquired hematologic dysfunction.
- To review severe drug-induced hematologic effects and drugs associated with multiple hematologic complications.
Main Methods:
- Literature review of drug-induced hematologic effects in critical care settings.
- Analysis of clinical presentations and causative agents for severe hematologic disorders.
Main Results:
- Clinicians must maintain a high index of suspicion for drug-induced hematologic dysfunction.
- Severe examples include drug-induced aplastic anemia, heparin-induced thrombocytopenia, and drug-induced thrombotic microangiopathy.
- Certain drugs, such as cisplatin and quinine, can induce multiple distinct hematologic effects.
Conclusions:
- Concomitant medications should always be evaluated in the differential diagnosis of acquired hematologic dysfunction during critical illness.
- Awareness of specific drug-hematologic effect associations is crucial for timely diagnosis and management.